Product Data Sheet

Kynuramine dihydrochloride

Cat. No.: HY-119395B CAS No.: 36681-58-0 Molecular Formula: $C_9H_{14}Cl_2N_2O$ Molecular Weight: 237.13

Target: Monoamine Oxidase Pathway: **Neuronal Signaling**

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

$$O$$
 NH_2
 NH_2

HCI HCI

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (527.14 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.2171 mL	21.0855 mL	42.1710 mL
	5 mM	0.8434 mL	4.2171 mL	8.4342 mL
	10 mM	0.4217 mL	2.1085 mL	4.2171 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.77 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.77 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	$ \text{Kynuramine, an endogenously occurring amine, is a fluorescent substrate and probe of plasma amine oxidase} ^{[1][2]}. \\$
In Vitro	Kynuramine inhibits both presynaptic and postsynaptic α -adrenoceptors in vitro ^[2] . Kynuramine has been shown to act as a partial agonist on serotonin receptors in dog cerebral arteries ^[2] . Kynuramine (20 µg/mL) frequently causes a small contraction of the ileum but failed to alter the twitch response to cholinergic stimulation ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Kynuramine (0.064, 0.32, 1.6 or 8 μg; ICV; single does) may serve a physiological role in the modulation of female sexual behavior ^[3] . Kynuramine (1.25, 2.5 and 5.0 mg/kg; i.v.; single does) increases heart rate and blood pressure in pithed rats ^[4] .

MCE has not independe	ently confirmed the accuracy of these methods. They are for reference only.	
Animal Model:	Female rats ^[3] .	
Dosage:	0.064-8 μg.	
Administration:	Intraventricular administration; single does.	
Result:	Produced facilitation of lordosis behavior.	
Animal Model:	Male rats (about 200g) ^[4] .	
Dosage:	1.25-5.0 mg/kg.	
Administration:	i.v.; single does.	
Result:	Promoted heart rate and blood pressure.	

REFERENCES

- [1]. J B Massey, et al. Kynuramine, a fluorescent substrate and probe of plasma amine oxidase. J Biol Chem. 1977 Nov 25;252(22):8081-4.
- [2]. T D Johnson, An alpha-adrenoceptor inhibitory action of kynuramine. Eur J Pharmacol. 1981 Jul 10;72(4):351-6.
- [3]. S D Mendelson, et al. Intraventricular administration of l-kynurenine and kynuramine facilitates lordosis in the female rat. Eur J Pharmacol. 1987 Oct 27;142(3):447-51.
- [4]. T D Johnson, et al. Blood pressure and heart rate effects of kynuramine in pithed rats. Eur J Pharmacol. 1983 Feb 18;87(2-3):323-6.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA